Cargando…
Mobility endpoints in marketing authorisation of drugs: what gets the European medicines agency moving?
BACKGROUND: Mobility is defined as the ability to independently move around the environment and is a key contributor to quality of life, especially in older age. The aim of this study was to evaluate the use of mobility as a decisive outcome for the marketing authorisation of drugs by the European M...
Autores principales: | Jaeger, Simon U, Wohlrab, Martin, Schoene, Daniel, Tremmel, Roman, Chambers, Michael, Leocani, Letizia, Corriol-Rohou, Solange, Klenk, Jochen, Sharrack, Basil, Garcia-Aymerich, Judith, Rochester, Lynn, Maetzler, Walter, Puhan, Milo, Schwab, Matthias, Becker, Clemens |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8789320/ https://www.ncbi.nlm.nih.gov/pubmed/35077553 http://dx.doi.org/10.1093/ageing/afab242 |
Ejemplares similares
-
On the use of wearable sensors as mobility biomarkers in the marketing authorization of new drugs: A regulatory perspective
por: Viceconti, Marco, et al.
Publicado: (2022) -
O.5.2-7 Listening to the patients’ voice: a conceptual framework of the walking experience
por: Delgado-Ortiz, Laura, et al.
Publicado: (2023) -
Walking-related digital mobility outcomes as clinical trial endpoint measures: protocol for a scoping review
por: Polhemus, Ashley Marie, et al.
Publicado: (2020) -
Listening to the patients’ voice: a conceptual framework of the walking experience
por: Delgado-Ortiz, Laura, et al.
Publicado: (2023) -
The value of walking: a systematic review on mobility and healthcare costs
por: Wohlrab, Martin, et al.
Publicado: (2022)